The litigation surrounding the herbicide Paraquat continues as plaintiffs pursue claims linked to the chemical, which is associated with Parkinson’s Disease and banned in over 60 countries. As of early April, 5,859 claims are being processed in the Paraquat multidistrict litigation (MDL). This MDL framework streamlines legal proceedings, enhancing the management of evidence and testimonies. Nevertheless, many claims risk being dismissed due to unmet procedural requirements, such as delays in submitting Plaintiff Assessment Questionnaires (PAQs).
Recent developments have instilled renewed optimism among plaintiffs following various setbacks. On April 14, 2025, a joint statement was issued, potentially paving the way for settling most Paraquat cases. This followed the unexpected cancellation of the MDL case management conference.
The latest special master’s report emphasizes that nearly 100 cases are at risk of being dismissed for not meeting PAQ deadlines. Within multi-district litigations, the PAQ is vital as it acts as sworn testimony, allowing defendants to review and cross-examine evidence—a process akin to live testimony or a deposition. To maintain the viability of claims and prevent dismissal, timely PAQ submissions are crucial.
Negotiations are currently underway as parties involved have requested the court to pause the seventh circuit appeal, indicating that settlement discussions are progressing. Judge Nancy Rosenstengel supports this development, seeking to facilitate smooth proceedings. Over the next 60 days, details regarding settlement requirements and factors influencing claim values are expected to emerge.
There is optimism about these developments, indicating progress and a favorable outlook for plaintiffs seeking resolution in their Paraquat claims.